Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 269

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 269
---
except shares held under an employees’ share scheme) that are to be paid for wholly in cash must
be offered first to the existing holders of equity securities in proportion to the respective nominal amounts (i.e., par values) of their
holdings on the same or more favorable terms, unless a special resolution to the contrary has been passed or the articles of association
otherwise provide an exclusion from this requirement (which exclusion can be for a maximum of five years after which our shareholders’
approval would be required to renew the exclusion). In this context, “equity securities” means ordinary shares (and would
exclude shares that, with respect to dividends or capital, carry a right to participate only up to a specified amount in a distribution),
and any and all rights to subscribe for or convert securities into such ordinary shares. This differs from U.S. law, under which shareholders
generally do not have pre-emptive rights unless specifically granted in the certificate of incorporation or otherwise.

The Board seeks general authority to allot shares on a non-pre-emptive basis at each annual general meeting. By way of resolutions passed at our annual general meeting held on June 14, 2023, authorities were given to the directors to generally allot shares in the Company, or to grant rights to subscribe for or to convert or exchange any security into shares in the Company, up to an aggregate nominal amount of £140,000,000, for a period up to the conclusion of our annual general meeting to be held in 2026. At our annual general meeting held on June 13, 2024, authorities were given to the directors to generally allot shares in the Company, or to grant rights to subscribe for or to convert or exchange any security into shares in the Company, up to an aggregate nominal amount of £949,426.90 for a period up to the conclusion of our annual general meeting to be held in 2027. Pre-emptive rights under the Companies Act will not apply in respect of allotment of shares for cash made pursuant to such authority.

Transfer of Shares

Any certificated shareholder
may transfer all or any of his shares by an instrument of transfer in the usual common form or in any other manner which is permitted
by the Companies Act and approved by the Board of Directors. Any written instrument of transfer shall be signed by or on behalf of the
transferor and (in the case of a partly paid share) the transferee.

All transfers of uncertificated
shares shall be made in accordance with